Evidence map›Paper›PMID 34587383›Full record

Trial reportThe New England journal of medicine2021

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.

David M Weinreich, Sumathi Sivapalasingam, Thomas Norton, Shazia Ali, Haitao Gao, Rafia Bhore, Jing Xiao, Andrea T Hooper, Jennifer D Hamilton, Bret J Musser and 31 more

2 registry-linked trialsOpen access · greenAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The New England journal of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 413 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
413citing papers in PubMed, 11 pooled it
37.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04425629 phase3terminatednot on this map

A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19

TypeinterventionalSponsorRegeneron PharmaceuticalsRan2020 to 2022Enrolled10,078ConditionsCOVID-19Armscasirivimab+imdevimab combination therapy
NCT05205759 phase3terminatednot on this map

Adaptive, Randomized, Non-inferiority Trial to Evaluate the Efficacy of Monoclonal Antibodies in Outpatients With Mild or Moderate COVID-19

TypeinterventionalSponsorAzienda Ospedaliera Universitaria Integrata VeronaRan2021 to 2022Enrolled319ConditionsCOVID-19ArmsBamlanivimab Etesevimab, Sotrovimab, Casirivimab-Imdevimab
3 · Its place in the literature

Who cites it

413 citing papers in PubMed, 11 syntheses or guidelines pooled it, 632 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Guideline
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2025
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

353 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors at 1 institution in 1 country.

David M WeinreichFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Sumathi SivapalasingamFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Thomas NortonFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Shazia AliFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Haitao GaoFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Rafia BhoreFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Jing XiaoFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Andrea T HooperFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Jennifer D HamiltonFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Bret J MusserFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Diana RofailFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Mohamed HusseinFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Joseph ImFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Dominique Y AtmodjoFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Christina PerryFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Cynthia PanFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Adnan MahmoodFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Romana HosainFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
John D DavisFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).ORCID 0000-0001-6282-1670
Kenneth C TurnerFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Alina BaumFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Christos A KyratsousFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Yunji KimFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Amanda CookFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Wendy KampmanFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Lilia Roque-GuerreroFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Gerard AcloqueFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Hessam AazamiFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Kevin CannonFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
J Abraham Simón-CamposFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Joseph A BocchiniFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Bari KowalFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
A Thomas DiCioccioFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Yuhwen SooFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Gregory P GebaFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Neil StahlFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Leah LipsichFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Ned BraunsteinFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Gary HermanFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
George D YancopoulosFrom Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) - both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) - both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington, Wilmington, NC (K.C.); Köhler and Milstein Research, Hospital General Agustín O'Horan, Mérida, Mexico (J.A.S.-C.); and the Willis-Knighton Physician Network, Shreveport, LA (J.A.B).
Trial Investigators
Anna Needs Neuroblastoma Answers · US

Funding

Biomedical Advanced Research and Development Authority Not applicableRegeneron Pharmaceuticals Not applicable
6 · The paper itself

Abstract

backgroundIn the phase 1-2 portion of an adaptive trial, REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of medical visits in patients with coronavirus disease 2019 (Covid-19). REGEN-COV has activity in vitro against current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.

methodsIn the phase 3 portion of an adaptive trial, we randomly assigned outpatients with Covid-19 and risk factors for severe disease to receive various doses of intravenous REGEN-COV or placebo. Patients were followed through day 29. A prespecified hierarchical analysis was used to assess the end points of hospitalization or death and the time to resolution of symptoms. Safety was also evaluated.

resultsCovid-19-related hospitalization or death from any cause occurred in 18 of 1355 patients in the REGEN-COV 2400-mg group (1.3%) and in 62 of 1341 patients in the placebo group who underwent randomization concurrently (4.6%) (relative risk reduction [1 minus the relative risk], 71.3%; P<0.001); these outcomes occurred in 7 of 736 patients in the REGEN-COV 1200-mg group (1.0%) and in 24 of 748 patients in the placebo group who underwent randomization concurrently (3.2%) (relative risk reduction, 70.4%; P = 0.002). The median time to resolution of symptoms was 4 days shorter with each REGEN-COV dose than with placebo (10 days vs. 14 days; P<0.001 for both comparisons). REGEN-COV was efficacious across various subgroups, including patients who were SARS-CoV-2 serum antibody-positive at baseline. Both REGEN-COV doses reduced viral load faster than placebo; the least-squares mean difference in viral load from baseline through day 7 was -0.71 log

conclusionsREGEN-COV reduced the risk of Covid-19-related hospitalization or death from any cause, and it resolved symptoms and reduced the SARS-CoV-2 viral load more rapidly than placebo. (Funded by Regeneron Pharmaceuticals and others; ClinicalTrials.gov number, NCT04425629.).

Indexed as

COVID-19 Drug TreatmentAdolescentAdultAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntiviral AgentsCOVID-19Dose-Response Relationship, DrugDouble-Blind MethodDrug CombinationsFemaleHospitalizationHumansKaplan-Meier EstimateMaleMiddle AgedAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntiviral Agentscasirivimab and imdevimab drug combinationDrug Combinations

Identifiers

PMID34587383
PMCPMC8522800
OpenAlexW3204153794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.